The US Food and Drug Administration has reiterated concerns about the sufficiency of clinical data supporting Replimune’s experimental skin cancer treatment. In a recent regulatory review, agency staff highlighted gaps that could delay or derail approval, despite the therapy’s potential as a novel immunotherapy for advanced cutaneous squamous cell carcinoma. The development adds fresh uncertainty to Replimune’s regulatory timeline and underscores the challenges of bringing new oncology drugs to market.
The FDA has once again raised red flags over Replimune’s bid to secure approval for its investigational skin cancer therapy, RP1. In a staff review released ahead of an upcoming advisory committee meeting, regulators questioned whether the company’s clinical data sufficiently demonstrate the drug’s efficacy and safety for patients with advanced cutaneous squamous cell carcinoma, a form of non melanoma skin cancer.
RP1, an oncolytic immunotherapy designed to selectively infect and kill tumor cells while stimulating an immune response, has been under FDA scrutiny for months. The agency’s latest concerns echo previous feedback, suggesting Replimune may need to provide additional evidence before gaining regulatory clearance. The therapy is being evaluated as a monotherapy and in combination with other treatments, including checkpoint inhibitors.
DISCUSSION (0)